Pfizer Inc. (NYSE:PFE) is considered one of the most undervalued large cap stocks to invest in now, with Cantor Fitzgerald raising the price target to $27 and maintaining a Neutral rating on the shares. The firm expects a quiet earnings call with investor focus on VESPER-3 obesity data.

Positive results from Cohort 3 of the pivotal Phase 3 BREAKWATER trial show that Pfizer’s BRAFTOVI combination provides a durable response for patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer. The study showed a statistically significant and clinically meaningful objective response rate compared to standard-of-care regimens.

Pfizer Inc. (NYSE:PFE) is involved in the discovery, development, manufacture, and distribution of biopharmaceutical products worldwide. The company offers medicines and vaccines in various therapeutic areas, contributing to its position in the market.

While Pfizer has potential as an investment, some believe AI stocks offer greater upside potential with less downside risk. For those looking for an undervalued AI stock that could benefit from Trump-era tariffs and onshoring trends, further research is recommended.

For more insights on potential stock options, consider exploring the articles “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” for investment opportunities. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Cantor Fitzgerald Raises Pfizer (PFE) PT to $27 Amid Shifting Obesity Data Focus